

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P. D. Dox 1450
Alexandria, Virginia 22313-1450
www.usplo.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/209,541		12/11/1998	ANNA GUTOWSKA	E-1537-CIP	E-1537-CIP 6863 EXAMINER	
32215	7590	04/08/2004		EXAM		
KLARQUIST SPARKMAN, LLP MULLIS, JEFI					EFFREY C	
121 SW SAL	MON ST	TREET, SUITE 1600			D . DED	
ONE WORLD TRADE CENTER				ART UNIT	PAPER NUMBER	
PORTLAND			1711			

DATE MAILED: 04/08/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

				me				
		Application No.	Applicant(s)					
		09/209,541	GUTOWSKA, ANNA					
Office Action Summary		Examiner	Art Unit					
		Jeffrey C. Mullis	1711					
Period fo	The MAILING DATE of this communication	appears on the cover sheet	with the correspondence address					
	ORTENED STATUTORY PERIOD FOR RE	PLY IS SET TO EXPIRE 3	MONTH(S) FROM					
THE - Exte after - If the - If NO - Failu Any	MAILING DATE OF THIS COMMUNICATIOnsions of time may be available under the provisions of 37 CFF SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a period for reply is specified above, the maximum statutory perior to reply within the set or extended period for reply will, by streply received by the Office later than three months after the med patent term adjustment. See 37 CFR 1.704(b).	N. R 1.136(a). In no event, however, may reply within the statutory minimum of riod will apply and will expire SIX (6) N atute, cause the application to become	y a reply be timely filed thirty (30) days will be considered timely. MONTHS from the mailing date of this communic e ABANDONED (35 U.S.C. § 133).	cation.				
Status								
1)⊠	Responsive to communication(s) filed on 2	5 March 2004.						
2a)□	•	This action is non-final.						
3)□	Since this application is in condition for allo	wance except for formal m	atters, prosecution as to the meri	ts is				
,—	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposit	ion of Claims							
4)⊠	Claim(s) 31-36 is/are pending in the applica	ation.						
	4a) Of the above claim(s) is/are withdrawn from consideration.							
5)	Claim(s) is/are allowed.							
6)⊠	☐ Claim(s) <u>31-36</u> is/are rejected.							
7)	Claim(s) is/are objected to.							
8)[Claim(s) are subject to restriction an	d/or election requirement.						
Applicat	ion Papers							
9)[The specification is objected to by the Exam	niner.						
10)	D) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11)[The oath or declaration is objected to by the	Examiner. Note the attacl	ned Office Action or form PTO-15	2.				
Priority (under 35 U.S.C. § 119		•					
	Acknowledgment is made of a claim for fore All b) Some * c) None of: 1. Certified copies of the priority docum 2. Certified copies of the priority docum 3. Copies of the certified copies of the papplication from the International But	ents have been received. ents have been received in priority documents have be	n Application No	•				
* 0	See the attached detailed Office action for a	, , , , , , , , , , , , , , , , , , , ,	not received					
`	see the attached detailed Office action for a	nat of the definied copies i	iot received.					
Attachmen			_					
	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948)		w Summary (PTO-413) No(s)/Mail Date					
3) 🔲 Infor	mation Disclosure Statement(s) (PTO-1449 or PTO/SB rr No(s)/Mail Date	r	of Informal Patent Application (PTO-152)					

Application/Control Number: 09/209,541

Art Unit: 1711

The finality of the Office action 9-30-03 is hereby withdrawn. All remaining previous rejections are hereby withdrawn.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 32-43 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 32-46 of U.S. Patent No. 6,296,831. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims do not exclude radioactive isotopes and in fact embrace therapeutic isotopes as is embraced by

the patent claims.

This action is not being made FINAL.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Seidleck, can be reached on (571) 272-1078. The fax phone number for this Group is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-0994.

Application/Control Number: 09/209,541

Art Unit: 1711

J. Mullis:cdc March 31, 2004

Primary Examiner
Art Unit 1711